Verrica FDA approval of YCANTH for molluscum and Q2 net loss $11M; cash runway to Q1 2025

Verrica Pharmaceuticals Inc.

2023-Q2 EPS reported -$0.40 revenue$219,000

FDA approved YCANTH (cantharidin) on July 21 for molluscum in patients 2+; launch by Sep 2023.
Closed $125M debt facility with OrbiMed; drew $50M, up to $75M additional; cash extends into Q1 2025.
Q2 GAAP net loss $11.0M ($0.24/share) vs $10.2M loss in prior year; non-GAAP loss $9.4M.
Expanding Part 2 enrollment of VP-315 Phase 2 trial for basal cell carcinoma to accelerate development.
Cash and equivalents $55.1M at June 30, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Verrica Pharmaceuticals Inc. reported financial results for six months ended June 30, 2023.

Period: six months ended June 30, 2023
Result: reported results

Exact text from the filing

Verrica Pharmaceuticals Inc. (the " Registrant ") issued a press release announcing its financial results for the quarter and six months ended June 30, 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Verrica Pharmaceuticals Inc. reported second quarter ended June 30, 2023 results: net income net loss on a GAAP basis was $11.0 million, or $0.24 per share, EPS net loss on a GAAP basis was $11.0 million, or $0.24 per share.

Period: second quarter ended June 30, 2023
Net income: net loss on a GAAP basis was $11.0 million, or $0.24 per share
EPS: net loss on a GAAP basis was $11.0 million, or $0.24 per share
Result: reported results

Exact text from the filing

Verrica Pharmaceuticals Inc. (the " Registrant ") issued a press release announcing its financial results for the quarter and six months ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Verrica Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-205590

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.